Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications

MT Newswires Live

2024-12-20

Sight Sciences (SGHT) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield "meaningful" cost savings based on the results of a budget impact analysis.

The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.

A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2492380344"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492380344\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492380344?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 06:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492380344","market":"hk","top_or_hot":-1,"title":"Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications","media":"MT Newswires Live","content":"<html><body><p> Sight Sciences (SGHT) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield \"meaningful\" cost savings based on the results of a budget impact analysis.</p><p>The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.</p><p>A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-20 06:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Sight Sciences (SGHT) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield \"meaningful\" cost savings based on the results of a budget impact analysis.</p><p>The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.</p><p>A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492380344","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492380344","pubTimestamp":1734648481,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sight Sciences  said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield \"meaningful\" cost savings based on the results of a budget impact analysis.The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","SGHT":"Sight Sciences, Inc.","BK4082":"医疗保健设备"},"translate_title":"与现有处方药相比，Sight Sciences针对干眼症的TearCare治疗可节省成本","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGHT":1},"content_text":"Sight Sciences (SGHT) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield \"meaningful\" cost savings based on the results of a budget impact analysis.The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}